NCT06144606View on ClinicalTrials.gov

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 26, 2023

Primary Completion Date

November 15, 2028

Study Completion Date

November 15, 2028

Conditions
B-Cell Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia
Interventions
DRUG

Tecartus

Tecartus is a CD19 directed CAR T-cell therapy that utilizes CD28 costimulatory and CD3 zeta stimulatory domains. Tecartus is manufactured from purified autologous T-cells via retroviral transduction with a median time to product release of 13 days.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

Kite, A Gilead Company

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER